166 related articles for article (PubMed ID: 25332032)
21. History, development and future of cancer screening in Australia.
Olver IN; Roder D
Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765858
[TBL] [Abstract][Full Text] [Related]
22. The impact of stratifying by family history in colorectal cancer screening programs.
Goede SL; Rabeneck L; Lansdorp-Vogelaar I; Zauber AG; Paszat LF; Hoch JS; Yong JH; van Hees F; Tinmouth J; van Ballegooijen M
Int J Cancer; 2015 Sep; 137(5):1119-27. PubMed ID: 25663135
[TBL] [Abstract][Full Text] [Related]
23. Bowel cancer screening--a role for general practice.
Foreman L
Aust Fam Physician; 2009 Apr; 38(4):200-3. PubMed ID: 19350068
[TBL] [Abstract][Full Text] [Related]
24. Colorectal cancer screening.
Leggett BA; Hewett DG
Intern Med J; 2015 Jan; 45(1):6-15. PubMed ID: 25582937
[TBL] [Abstract][Full Text] [Related]
25. Faecal occult blood testing (FOBT)-based colorectal cancer screening trends and predictors of non-use: findings from the South Australian setting and implications for increasing FOBT uptake.
Todorov K; Wilson C; Sharplin G; Corsini N
Aust Health Rev; 2018 Feb; 42(1):45-52. PubMed ID: 28248632
[TBL] [Abstract][Full Text] [Related]
26. Factors associated with participation in colorectal cancer screening in Australia: Results from the 45 and Up Study cohort.
He E; Lew JB; Egger S; Banks E; Ward RL; Beral V; Canfell K
Prev Med; 2018 Jan; 106():185-193. PubMed ID: 29109015
[TBL] [Abstract][Full Text] [Related]
27. Increasing bowel cancer screening using SMS in general practice: the SMARTscreen cluster randomised trial.
McIntosh JG; Jenkins M; Wood A; Chondros P; Campbell T; Wenkart E; O'Reilly C; Dixon I; Toner J; Martinez-Gutierrez J; Govan L; Emery JD
Br J Gen Pract; 2024 Apr; 74(741):e275-e282. PubMed ID: 38164588
[TBL] [Abstract][Full Text] [Related]
28. The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: Microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline.
Peterse EFP; Meester RGS; Siegel RL; Chen JC; Dwyer A; Ahnen DJ; Smith RA; Zauber AG; Lansdorp-Vogelaar I
Cancer; 2018 Jul; 124(14):2964-2973. PubMed ID: 29846933
[TBL] [Abstract][Full Text] [Related]
29. Increasing bowel cancer screening participation: integrating population-wide, primary care and more targeted approaches.
Lofti-Jam KL; O'Reilly CL; Feng CS; Wakefield MA; Durkin S; Broun KH
Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384890
[TBL] [Abstract][Full Text] [Related]
30. Analysis of colorectal cancer outcomes for the Australian National Bowel Cancer Screening Program.
;
Asia Pac J Clin Oncol; 2016 Mar; 12(1):22-32. PubMed ID: 26803949
[TBL] [Abstract][Full Text] [Related]
31. Revised Australian national guidelines for colorectal cancer screening: family history.
Jenkins MA; Ait Ouakrim D; Boussioutas A; Hopper JL; Ee HC; Emery JD; Macrae FA; Chetcuti A; Wuellner L; St John DJB
Med J Aust; 2018 Nov; 209(10):455-460. PubMed ID: 30359558
[TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.
Cenin DR; Naber SK; de Weerdt AC; Jenkins MA; Preen DB; Ee HC; O'Leary PC; Lansdorp-Vogelaar I
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):10-21. PubMed ID: 31748260
[TBL] [Abstract][Full Text] [Related]
33. Initial impact of Australia's National Bowel Cancer Screening Program.
Ananda SS; McLaughlin SJ; Chen F; Hayes IP; Hunter AA; Skinner IJ; Steel MC; Jones IT; Hastie IA; Rieger NA; Shedda S; Compston DJ; Gibbs P
Med J Aust; 2009 Oct; 191(7):378-81. PubMed ID: 19807627
[TBL] [Abstract][Full Text] [Related]
34. Population-level impact of the BMJ Rapid Recommendation for colorectal cancer screening: a microsimulation analysis.
van Duuren LA; Bulliard JL; Mohr E; van den Puttelaar R; Plys E; Brändle K; Corley DA; Froehlich F; Selby K; Lansdorp-Vogelaar I
BMJ Open Gastroenterol; 2024 May; 11(1):. PubMed ID: 38724254
[TBL] [Abstract][Full Text] [Related]
35. [Estimated impact of the current colorectal screening program in France].
Barré S; Leleu H; Vimont A; Kaufmanis A; Gendre I; Taleb S; De Bels F
Rev Epidemiol Sante Publique; 2020 Jun; 68(3):171-177. PubMed ID: 32417153
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
Murphy J; Halloran S; Gray A
BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
[TBL] [Abstract][Full Text] [Related]
37. Realized impact of COVID-19 related disruptions on the National Bowel Cancer Screening Program.
Irwin MP; Dutta T; Jambor MA; Morgan MJ; Turner CE; Liang Y
ANZ J Surg; 2024 Feb; ():. PubMed ID: 38345127
[TBL] [Abstract][Full Text] [Related]
38. Colonoscopy requirements of population screening for colorectal cancer in New Zealand.
Green T; Richardson A; Parry S
N Z Med J; 2012 Jun; 125(1356):85-95. PubMed ID: 22729063
[TBL] [Abstract][Full Text] [Related]
39. Effects of screening and universal healthcare on long-term colorectal cancer mortality.
Lee YC; Hsu CY; Chen SL; Yen AM; Chiu SY; Fann JC; Chuang SL; Hsu WF; Chiang TH; Chiu HM; Wu MS; Chen HH
Int J Epidemiol; 2019 Apr; 48(2):538-548. PubMed ID: 30184208
[TBL] [Abstract][Full Text] [Related]
40. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
